行情

CYAD

CYAD

Celyad Oncology
NASDAQ

实时行情|Nasdaq Last Sale

4.270
-0.060
-1.39%
已收盘, 16:00 09/23 EDT
开盘
4.270
昨收
4.330
最高
4.332
最低
4.210
成交量
6
成交额
--
52周最高
10.31
52周最低
3.760
市值
6,615.92万
市盈率(TTM)
-3.3943
分时
5日
1月
3月
1年
5年
Celyad Oncology 宣布 2021 年 9 月会议时间表
MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, ...
GlobeNewswire · 09/01 05:00
HC Wainwright & Co. 维持对 Celyad Oncology 的买入,将目标价下调至 15 美元
HC Wainwright & Co. analyst Edward White maintains Celyad Oncology (NASDAQ:CYAD) with a Buy and lowers the price target from $17 to $15.
Benzinga · 08/06 10:07
——HC Wainwright 将 Celyad Oncology 的目标价从 17 美元上调至 15 美元,维持买入评级
MT Newswires · 08/06 09:17
每日生物技术脉搏:默克报告了积极的 Keytruda 读数,尽管第二季度节拍,Moderna 下滑,拜耳以高达 $2B 的价格购买 Vividion,GlycoMimetics 获得新的首席执行官
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
Celyad Oncology 报告 2021 年上半年财务业绩和近期业务亮点
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial resul...
GlobeNewswire · 08/04 20:01
生物技术的未来一周(8 月 1 日至 7 日):生物制药收益加快,伊顿公学等待 FDA 的决定,专注于待定的临床读数和 IPO
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 08/01 14:13
Celyad Oncology 将公布 2021 年上半年财务业绩并主持电话会议
Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2021 fin...
GlobeNewswire · 07/29 05:00
Celyad Oncology 重点介绍新的 CAR T 产品,并提供数据更新
Celyad Oncology (CYAD) highlights new preclinical allogeneic armored CAR T candidate developed from its shRNA platform.The submission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate,
Seekingalpha · 07/20 20:12
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CYAD最新的财务预测,通过CYAD每股收益,每股净资产,每股现金流等数据分析Celyad Oncology近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CYAD价格均价为17.39,最高价位19.87,最低价为14.90。
EPS
机构持股
总机构数: 13
机构持股: 28.39万
持股比例: 1.83%
总股本: 1,549.40万
类型机构数股数
增持
1
900
建仓
2
17.20万
减持
2
67.08万
平仓
1
87
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.87%
制药与医学研究
+1.27%
高管信息
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
暂无数据
CYAD 简况
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

微牛提供Celyad Oncology SA(NASDAQ-CYAD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CYAD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CYAD股票基本功能。